In The News

HepQuant to Present at Key Liver Conferences to Highlight Applications of HepQuant DuO™ – a Quantitative Liver Health Test

Recent clinical data demonstrates how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression and evaluate response to resmetirom therapy in patients with compensated advanced chronic liver disease (cACLD). Denver, CO – March 17, 2025 – HepQuant, LLC continues to expand clinical availability of…

HepQuant Introduces HepQuant DuO™, a Quantitative Liver Function Test for Patients with Liver Disease with 6 Presented Abstracts at The Liver Meeting 2024

“As it awaits key readout, Hepion boosts confidence in NASH drug hopeful via shorter study”

HepQuant Named One of Colorado’s Best Health Diagnostics Companies

Hepion Pharma Announces First Dosing in Phase 2b Clinical Trial with HepQuant

Tackling Liver Disease with a Multimodal Cyclophilin Inhibitor

Statins Show Promise for Advanced Liver Failure and Cirrhosis